目的 建立鹽酸安羅替尼膠囊藥物利用評價（DUE）標(biāo)準(zhǔn)，并以加權(quán)TOPSIS法對鹽酸安羅替尼膠囊用藥的合理性進行評價，為臨床合理性用藥指導(dǎo)提供借鑒。方法 將鹽酸安羅替尼膠囊說明書作為基礎(chǔ)，并根據(jù)鹽酸安羅替尼膠囊實際應(yīng)用情況及相關(guān)的診療指南進行DUE標(biāo)準(zhǔn)的制定，并從醫(yī)院信息系統(tǒng)（HIS）系統(tǒng)中采用隨機的方法選取2022年1月—2024年8月以鹽酸安羅替尼膠囊治療的病歷共180份，用加權(quán)TOPSIS法評價患者用藥的合理性。結(jié)果 180份病例中相對接近成都（C_i）最高為1，最低為0.327，C_i≥80%有96例（53.33%），60%≤C_i＜80%有64例（35.56%），C_i＜60%有20例（11.11%）；用藥不合理主要集中在適應(yīng)證、用藥監(jiān)護、不良反應(yīng)監(jiān)測與處理。結(jié)論 以加權(quán)TOPSIS法對鹽酸安羅替尼膠囊用藥合理性進行評價，其評價結(jié)果能充分地反映其在臨床應(yīng)用中的合理性，且操作更方便、更直觀地指導(dǎo)臨床用藥。

Objective To establish the drug utilization evaluation (DUE) criteria of Anrotinib Hydrochloride Capsules and evaluate the rationality of drug use of Anrotinib Hydrochloride Capsules based on the weighted TOPSIS method, so as to provide reference for clinical rationality of drug use guidance. Methods The instruction manual of Anrotinib Hydrochloride Capsules was used as the basis, and the DUE criteria were formulated according to the actual application of Anrotinib Hydrochloride Capsules and relevant diagnosis and treatment guidelines, and a total of 180 medical records treated with Anrotinib Hydrochloride Capsules during January 2022 to August 2024 were selected from HIS system using randomized method, and the reasonableness of the patient’s medication was evaluated using the weighted TOPSIS method. Results The highest C_i among 180 cases was 1, and the lowest was 0.327, and there were 96 cases (53.33%) with C_i ≥ 80%, 64 cases (35.56%) with 60% ≤ C_i < 80%, and 20 cases (11.11%) with C_i < 60%, the irrationality of medication use was mainly focused on indications, medication supervision, and the monitoring and treatment of adverse reactions. Conclusion The evaluation of the rationality of the medication of Anrotinib Hydrochloride Capsules by weighted TOPSIS method can fully reflect its rationality in clinical application, and the operation is more convenient and more intuitive to guide the clinical use of medication.

R979.1